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Streptococcus pneumoniae has two
type II DNA-topoisomerases (DNA-gyrase
and DNA topoisomerase IV) and a single type
I enzyme (DNA-topoisomerase I, TopA), as
demonstrated here. While fluoroquinolones
target type II enzymes, antibiotics efficiently
targeting TopA have not yet been reported.
Eighteen alkaloids (7 aporphine and 11
phenanthrenes) were semisynthesized from
boldine and used to test both inhibition of
TopA activity and of cell growth. Two
phenanthrenes (seconeolitsine and N-
methylseconeolitsine) effectively inhibited
both TopA activity and cell growth at
equivalent concentrations (17 μM). Evidence
for in vivo TopA targeting by seconeolitsine
was provided by the protection of growth
inhibition in a S. pneumoniae culture in which
the enzyme was overproduced. Additionally,
hypernegative supercoiling was observed in
an internal plasmid after drug treatment.
Furthermore, a model of pneumococcal TopA
was made based on the crystal structure of E.
coli TopA. Docking calculations indicated
strong interactions of the alkaloids with the
nucleotide-binding site in the closed protein
conformation, which correlated with their
inhibitory effect. Finally, although
seconeolitsine and N-methly-seconeolitsine
inhibited TopA and bacterial growth, they
did not affect human cell viability. Therefore,
these new alkaloids can be envisaged as new
therapeutic candidates for the treatment of S.
pneumoniae infections resistant to other
antibiotics.
Antibiotic resistance in bacterial
pathogens is a serious clinical problem. This
problem affects to Streptococcus pneumoniae
(the pneumococcus) that in addition to be one of
the principal human pathogens, is the main
ethyological agent of community-acquired
pneumonia. Annually, about 1 million children
aged <5 years die of pneumococcal pneumonia,
meningitis, and/or sepsis worldwide (1).
Resistance to currently used antimicrobial drugs
for the treatment of pneumococcal infections,
including beta-lactams and macrolides, has
spread worldwide in the last two decades (2).
The new fluoroquinolones, such as levofloxacin
and moxifloxacin, which act on type II DNA
topoisomerases, are nowadays therapeutic
alternatives for treatment of adult patients with
community-acquired pneumonia, (3). However,
although resistance to fluoroquinolones in S.
pneumoniae is still lower than 3% (4), an
increase in resistance is likely to occur.
DNA topoisomerases participate in
almost all cellular functions involving DNA
transactions (5). They solve the topological
problems associated with DNA replication,
transcription, and recombination. In addition,
these enzymes fine-tune the steady-state level of
DNA supercoiling both facilitating protein
interactions with the DNA and preventing
excessive supercoiling that is deleterious. In
bacteria, the homeostasis of DNA supercoiling is
maintained by the opposing activities of
topoisomerases that relax DNA, and gyrase that
introduces negative supercoils. The
transcriptional response to DNA relaxation
involves genes coding for all the DNA
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topoisomerases from S. pneumoniae:
topoisomerase I, topoisomerase IV, and DNA
gyrase. Relaxation of DNA triggers the
transcriptional up-regulation of gyrase and the
down-regulation of topoisomerase I and
topoisomerase IV (6).
The enzymatic activity of
topoisomerases involves DNA cleavage and the
formation of a transient phosphodiester bond
between a catalytic tyrosine residue in the
protein and one of the ends of the broken strand.
DNA topology is modified during the lifetime of
the covalent intermediate, and the enzyme is
released as the DNA is religated.
Topoisomerases are classified into two types
based on their DNA cleavage pattern: type I
enzymes that only cleave one DNA strand, and
type II enzymes that cleave both strands. The
type II topoisomerases are tetrameric proteins
formed by two different subunits: GyrA2GyrB2
for gyrase and ParC2ParE2 for topoisomerase IV.
Fluoroquinolones inhibit type II enzymes and
mainly affect chromosome replication. They
also stabilize a reaction intermediate in which
the enzymes are covalently linked to the DNA
originating double-stranded breaks that lead to
cell death (7). Genetic and biochemical studies
have shown that in Gram-positive bacteria,
including S. pneumoniae, topoisomerase IV is
the primary target for most fluoroquinolones and
gyrase is a secondary target (8, 9). The type I
enzymes are classified as either subfamily type
IA if the protein links to the 5’ phosphate or
subfamily type IB when the protein attaches to
the 3’ phosphate. There is extensive sequence
similarity among members of the same
subfamily (10) but almost no sequence or
structural similarity between the two subfamilies
(11,12). All bacterial type I topoisomerases are
type IA enzymes. The overall structure of
Escherichia coli topoisomerase I presents four
domains with the active site located at the
intersection of domains I and III where the
catalytic Tyr319 residue is placed (13). The
proposed mechanism of action involves the
opening of the enzyme through a large
conformational change that separates domains II
and III from the rest of the protein (14). A
nucleotide-binding site has been identified in E.
coli at the interface of domains I, III and IV.
This nucleotide-binding site, the only one
formed by residues from the three domains in
the closed conformation, has been proposed to
bind the region of the 3’-OH end of the cleaved
DNA strand (14).
Cheng et al (15) have recently described
one phenanthrene alkaloid able to inhibit the
relaxation activity of E. coli topoisomerase I.
However, no significant inhibition in cell growth
was observed. The aim of the present study was
to investigate the therapeutic potential of
targeting pneumococcal topoisomerase I. For
this purpose new alkaloid inhibitors of its
enzymatic activity have been developed and
tested for their effects on DNA supercoiling.
Furthermore, their effect on cell growth was also
evaluated.
Experimental Procedures
Bacterial strains, growth and
transformation of bacteria- S. pneumoniae was
grown in a casein hydrolysate-based medium
with 0.3% sucrose (AGCH) as energy source
and transformed with chromosomal or plasmid
DNA as described previously (16). Minimal
inhibitory concentrations (MICs) were
determined in the same medium by the
microdilution method according to the National
Committee for Clinical Laboratory Standards
(NCCLS) (17). The MIC was defined as the
lowest concentration of drug without visible
growth.
Structures of N-metilseconeolitsine and
seconeolitsine- The structural elucidation of
compounds 16 (N-metilseconeolitsine,) and 17
(seconeolitsine) were determined by 1H and 13C-
NMR using one-dimensional and two-
dimensional (homonuclear COSY, heteronuclear
multiple quantum coherence HMQC, and
heteronuclear multiple bond connectivity
HMBC) experiments in conjunction with mass
spectral analysis and UV spectrum. Parameters
were the following:
-Seconeolitsine: C19 H17 N O4; mp 111-113ºC;
UV (MeOH): max (log ) = 262 (0.40), 289
(0.12), 325 (0.07) nm; 1H-RMN (DMSO-d6) δ
(ppm): 2.32 (3H, s, N-CH3), 2.76 (2H, m, CH2α),
3.14 (2H, m, CH2β), 6.16 (2H, s, OCH2O-6,7),
6.24 (2H, s, OCH2O-3,4), 7.22 (1H, s, H-2), 7.40
(1H, s, H-8), 7.56 (1H, d, J= 9.3 Hz, H-9), 7.81
(1H, d, J= 9.3 Hz, H-10), 8.39 (1H, s, H-5); 13C-
RMN (DMSO-d6) δ (ppm): 32.88 (CH2β), 35.75
(NCH3), 52.73 (CH2α), 100.93 (OCH2O, C-3,4),
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101.48 (OCH2O, C-6,7), 104.37 (C-5), 105.19
(C-8), 110.29 (C-2), 116.28 (C-4a), 121.31 (C-
10), 123.44 (C-5a), 124.32 (C-9), 125.01 (C-
10a), 128.15 (C-8a), 131.33 (C-1), 140.64 (C-4),
144.03 (C-3), 147.03* (C-7) 147.10* (C-6); EI-
MS m/z (int. rel.)= 323 (10), 280 (100), 279
(32), 221 (2), 163 (14).
-N-metilseconeolitsine: C20 H19 N O4; mp 132-
134ºC; UV (MeOH): max (log ) = 262 (0.40),
289 (0.12), 325 (0.07) nm; 1H-RMN (DMSO-d6)
δ (ppm): 2.22 (6H, s, N-(CH3)2), 2.49 (2H, m,
CH2α), 3.12 (2H, m, CH2β), 6.17 (2H, s, OCH2O-
6,7), 6.25 (2H, s, OCH2O-3,4), 7.25 (1H, s, H-
2), 7.41 (1H, s, H-8), 7.57 (1H, d, J= 9.3 Hz, H-
9), 7.75 (1H, d, J= 9.3 Hz, H-10), 8.39 (1H, s,
H-5); 13C-RMN (DMSO-d6) δ (ppm): 30.79
(CH2β), 45.10 (N(CH3)2), 60.51 (CH2α), 100.94
(OCH2O, C-3,4), 101.48 (OCH2O, C-6,7),
104.39 (C-5), 105.19 (C-8), 110.29 (C-2),
116.28 (C-4a), 121.15 (C-10), 123.47 (C-5a),
124.40 (C-9), 124.90 (C-10a), 128.12 (C-8a),
131.50 (C-1), 140.60 (C-4), 144.05 (C-3),
146.80 (C-6) 146.80 (C-7); EI-MS m/z (int.
rel.)= 337 (100), 279 (63), 221 (5), 191 (5), 163
(58).
Cloning and expression of topA in E. coli-
The topA gene was amplified by PCR with 0.1
g of chromosomal DNA from S. pneumoniae
R6 and 1 M (each) synthetic oligonucleotide




3’). The 5’ end of topADOWN contained a
sequence including a PaeI restriction site (lower
case letters), topAUP2 included the GTG
initiation codon and topADOWN the sequence
complementary to the TAA stop codon
(underlined). Amplification was achieved with
an initial cycle of 2 min denaturation at 94 ºC, 1
min annealing at 55ºC, and 2.5 min polymerase
extension with Pfu high-fidelity polymerase
(Fermentas) at 72 ºC. Then 30 cycles of 2 min
94 ºC, 1 min at 55 ºC and 2.5 min at 72 ºC with
slow cooling at 10 ºC. Oligonucleotides were
removed (QIAquick PCR Purification Kit,
QIAGEN), cut with PaeI, cloned into plasmid
pQE1 digested with PaeI + PvuII, and
established in E. coli M15 (pREP4) (QIAGEN).
Sequencing with oligonucleotides pQE-seq3 (5’-
AGCTAGCTTGGATTCTCACC-3’) and pQE-
seq5 (5’-GAGGCCCTTTCGTCTTCA-3’) was
performed to confirm the cloning. The pQE1
vector/M15(pREP4) host cloning system permits
the hyperproduction of 6 His-tagged
recombinant proteins encoded by genes placed
under the control of a phage T5 promoter and
two lac operator sequences. The host strain
contains the low-copy plasmid pREP4 which
constitutively expresses the LacI repressor.
Expression of recombinant proteins encoded by
pQE vectors was induced by the addition of
isopropyl-β-D-thiogalactoside (IPTG) which 
binds to the LacI protein and inactivates it. This
inactivation allows the host cell’s RNA
polymerase to transcribe the sequences
downstream from the T5 promoter. A culture of
E. coli M15 (pREP4)/ pQE-SPNtopA was grown
at 37 oC in LB medium containing 250 g/ml of
ampicilin (to select pQE1) and 25 g/ml
kanamicin (to select pREP4) to DO620 = 0.6.
IPTG (1mM) was added and incubation
continued for 30 min. Cells were collected by
centrifugation, lysed at 4oC for 30 min in buffer
A (50 mM NaH2PO4 pH 8, 300 mM NaCl, 10
mM imidazol) and lisozyme (1mg/ml) and
sonicated for 5 min (10 times for 30 s, with 1
min cooling between each sonication) in a
Sonifier B-12 (Branson Co, Connetticut). Debris
was removed by centrifugation at 10.000  g for
20 min and the resulting supernatant dialyzed
overnight against buffer A. The TopA protein
was purified by affinity chromatography in Ni-
NTA (QIAGEN) column following
manufacturer’s instructions. Briefly, column (1
ml) was washed with 10 ml of buffer A and the
bound proteins eluted with 10 ml of buffer
containing imidazol at 60, 100, and 200 mM.
Fractions of 2 ml were collected and analyzed
by SDS-10% polyacrylamide gel and stained
with comassie blue. Fractions containing a
protein of the expected size were dialyzed
against buffer B (20 mM TrisHCl pH 8, 50 mM
KCl, 1mM DTT, 50% glicerol). The purified
protein was conserved at -20 oC. In these
conditions, TopA remains active for at least 12
months.
Cloning of topA under the control of Pmal
in S. pneumoniae- The topA gene was amplified
by PCR from strain R6 as described above
except that primer topAUP4 (5’-
CGCGCtctagaAGGTGTGATACTATGGCT -
3’) was used instead topAUP2. The 5’ end of
topAUP4 contained a sequence including an
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XbaI restriction site (lower case letters) and
included an ATG initiation codon (underlined).
The amplified fragment was cut with PaeI +
XbaI, cloned into plasmid pLS1RGFP (18)
digested with the same enzymes and established
in strain R6. Transformed bacteria were selected
in AGCH containing erythromycin (1 µg/ml).
Recombinant plasmids were identified by
digestion with HindIII + EcoRI and confirmed
by sequencing with oligonucleotides pLS1rF
(5’- GAGTATACTTATAAGTAACGCAAAC-
3’) and pLS1rR (5’-
TAGGTTGAGGCCGTTGAGCACC -3’).
Relaxation of pBR322 by TopA and
human TOPO1- Reactions were carried out in 15
or 100 l containing 0.5 g of supercoiled
plasmid pBR322 in 20 mM Tris HCl pH 8, 100
mM KCl, 10 mM MgCl2, 1 mM DTT, 50 g
BSA/ml. After 1 h incubation at 37oC in the
presence on TopA, the reaction was terminated
by 2 min incubation at 37ºC with 50 mM EDTA
and 1 h at 37oC with 1% SDS, 100 g/ml
proteinase K. Treatment with human TOPO1
(Inspiralis, Norwich, UK) was performed with
the buffer and conditions recommended by the
supplier. When required, samples were ethanol
precipitated and resuspended in H2O. Reaction
products were analyzed by electrophoresis in
1.2% agarose gels run at 18 V for 20 h.
Treatment with the alkaloids was performed by
preincubation of TopA or TOPO1 during 10 min
at 4 oC in a final volume of 15 l. DNA
quantification of agarose gels was done by
scanning densitometry after electrophoresis and
ethidium bromide (EtBr) staining. Quantification
of TopA activity was calculated by gel
densitometry using the Quantity One program
(Bio-Rad laboratories). To calculate activity, the
amount of the CCC form was determined and
divided by the total amount of DNA in each
well. IC50 (mean of at least three independent
determinations) was defined as the concentration
of drug required for a 50% reduction of
enzymatic activity.
Analysis of the topology of covalently
closed circles- Circular DNA molecules were
analyzed in neutral/neutral two-dimensional
agarose gels. The first dimension was run at 1.5
V/cm in a 0.4% agarose (Seakem; FMC
Bioproducts) gel in 1  Tris-borate-EDTA
(TBE) buffer for 1719 h at room temperature.
The second dimension was run at 7.5 V/cm in
1% agarose gel in 1  TBE buffer for 79 h at
4ºC. Chloroquine (Sigma) was added to the TBE
buffer in both, the agarose and the running
buffer. After electrophoresis gels were subjected
to Southern hybridization. Two probes were
used on two-dimensional agarose gels
transferred to nylon membrane (Inmobylon NY+,
Millipore). For the analysis of the supercoiling
level in pLS1 in vivo, a 240-bp PCR fragment
obtained from pLS1 as described (6) was used.
For the analysis of the enzymatic activity of
TopA, pBR322 plasmid was digested with
EcoRI + EcoRV and the ends filled with
byotinilated dNTPs by the Klenow polymerase
Fragment (Fermentas) and used as a probe.
Chemiluminiscent detection of DNA was
performed with the Phototope -Star kit (New
England Biolabs). Images were captured in a
VersaDoc MP400 system and analyzed with the
Quantity One program (BioRad).
Cytofluorometric analysis of neutrophil
apoptosis and survival. Human peripheral blood
neutrophils were obtained from buffy coats of
healthy donors by Ficoll Hypaque density
gradient centrifugation, as previously described
(19). Freshly isolated neutrophils were
resuspended in supplemented RPMI at 2 x 106
cells/ml. Twenty-five µl were cultured in a 96-
well plate containing 200 µl supplemented RPMI
during 24 h in the absence or presence of
compounds 16 and 17. Assessment of apoptosis
was performed by flow cytometry using annexin
V-FITC and propidium iodide (PI). The protocol
indicated by the manufacturer (Annexin-V-
Fluos; Roche Applied Science) was used as
previously outlined (20). Cells (1 x 104) were
analyzed in a Beckman Coulter Epics XL
(Fullerton, CA) and differentiated as early or
viable apoptotic (annexin V+, PI–), late apoptotic
and/or necrotic (annexin V+ and PI+), and viable
nonapoptotic (annexin V– and PI–) cells.
EtBr displacement assay-A total of 6 g
(300 l) of calf thymus DNA was diluted to 3 ml
with buffer (20 mM NaCl, 2 mM HEPES, 10
M EDTA, pH 7.4). Prior to analysis, 3 l of
EtBr (0.5 mg/ml) were added and allowed to
equilibrate 1 min. Aliquots of alkaloids were
then added and the fluorescence measured on an
Cary Eclipse Varian fluoresce
spectrophotometer after 1 min equilibration,
using excitation and emission wavelengths of
546 and 660 nm, respectively.
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Molecular modelling of topoisomerase I
from S. pneumoniae- The model was built on the
basis of the crystal structure of E. coli
topoisomerase I (PDB code: 1CY1). Amino acid
changes along the entire sequence were
performed using the O program (21), running in
a Silicon Graphics workstation. Side-chain
rotamers were chosen from a database of more
common conformers. The overall fold of the
model was energy minimized using the
minimiser algorithm implemented in the CNS
package (22). The stereo chemical quality of the
model was checked with the PROCHECK
program (23).
Three-dimensional structures of alkaloid
ligands and molecular docking- Boldine,
secoboldine, seconeolitsine, and N-methyl
seconeolitsine were used in the docking
calculations. The three-dimensional structures of
boldine and secoboldine were obtained from the
Cambridge Structural Database
(http://www.ccdc.cam.ac.uk/) with reference
codes HIHXUR and OLIDES respectively. The
three-dimensional structures of seconeolitsine
and N-methyl seconeolitsine were modelled on
the basis of the crystallographic structures of
boldine and secoboldine by using the Dundee
PRODRG2 Server (24). Stereochemistry of
ligands was checked with Mercury program
(25). Molecular docking was carried out using
GOLD (Genetic optimization for Ligand
Docking) software (26), that uses the Genetic
Algorithm (GA). This method allows a partial
flexibility of protein and full flexibility of the
ligand. The cavity was defined from to 10 Å
around Ser487, giving freedom of movement to
Asp101, Arg102, Arg156, Arg300, Arg485,
Asp543 and Glu546 in side chains rotamers. For
each of the 25 independent GA runs, a
maximum number of 100000 GA operations
were performed on a set of five groups with a
population size of 100 individuals. Default cut-
off values of 2.5 Å (dH-X) for hydrogen bonds
and 4.0 Å for van der Waals distance were
employed. When the top three solutions attained
RMSD values within 1.5 Å, GA docking was
terminated. The RMSD values for the docking
calculations are based on the RMSD matrix of
the ranked solutions. We observed that the best-
ranked solutions were always among the first 10
GA runs, and the conformation of molecules
based on the best fitness score was further
analyzed.
RESULTS
Characterization of the DNA
topoisomerase I of S. pneumoniae. We
performed a BLAST search for DNA
topoisomerases coding sequences in the S.
pneumoniae R6 genome (27)
(http://www.streppneumoniae.com/) and found
that, besides the genes coding the two type II
enzymes (gyrase and topoisomerase IV), gene
topA (spr1141) encodes an homologue of
bacterial topoisomerase I. The topoisomerase I
enzymes from E. coli and S. pneumoniae show
46.9% similarity on the whole sequence and
62% in the cleavage/ strand passage module
(Fig. 1A). The topA gene was amplified by PCR
from R6 chromosomal DNA with specific
oligonucleotides and cloned into the E. coli
plasmid pQE-1 rendering pQE-SPNtopA, which
carries the Met-(His)6-Gln-TopA fusion protein
under the control of the T5 promoter. This
plasmid was established into E. coli M15
(pREP4) and its T5 promoter was induced by
IPTG. The recombinant plasmid overproduced a
protein with apparent Mr 84 kDa, and an
apparent purity of 98% (Fig. 1B), which is in
agreement with the expected size of the fusion
protein (79.37 kDa for TopA + 5.23 kDa for the
N-terminal fusion). Total yield of purification
was 0.8 mg of purified TopA per liter of culture,
with a concentration of 80 g/ml and a specific
relaxation activity (see below) of 2.4 x 104 units/
mg.
To test DNA relaxation activity of
TopA, covalently-closed negatively supercoiled
(CCC) pBR322 plasmid (1.77 nM) was
incubated in the presence of different amounts of
the purified enzyme and the reaction products
analyzed in mono-dimensional agarose as
described (28, 29). TopA activity converted the
CCC plasmid in topoisomers with different
degrees of supercoiling that were observed as
discrete bands when the gel was run in the
absence of EtBr (Fig. 2A). However, all relaxed
topoisomers (RC) migrated as a single band
when the gel was run in the presence of
saturating concentrations of EtBr (Fig. 2B). A
unit of TopA enzymatic activity was defined as
the amount of enzyme being able to relax 50%
of the CCC substrate in 1h at 37ºC, and
corresponded to 42 ng (5 nM) of the purified
enzyme. As observed in other bacterial
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topoisomerase I enzymes, the pneumococcal
TopA did not relax positively-supercoiled DNA
(Fig. 2C). This was shown by the absence of
activity on CCC pBR322 treated with EtBr (Fig.
2C, lane +EtBr), which, at the high
concentration used, introduces positive
supercoiling. The activity was partially
recovered when the intercalating agent was
removed with isoamyl alcohol (Fig. 2C, lane ±
EtBr). An additional method to examine
pBR322 topoisomers distribution after TopA
treatment was two-dimensional agarose gel
electrophoresis in the presence of chloroquine
(30). This technique, which differs from the
classical two-dimensional chloroquine gels,
makes it possible to separate DNA molecules by
mass and shape. In the two-dimensional gel,
topoisomers appeared distributed in the
autoradiograms in a bubble-shaped arc, negative
supercoiled molecules were located on the right-
side and positive supercoiled ones on the left
(Figs 2D and 2E). In the absence of enzyme,
100% of the topoisomers had negative
supercoiling (Figs 2D). In the presence of 1 unit
(5 mM) of enzyme 56.8% and 43.2% were
negative and positive supercoiled topoisomers,
respectively. In the presence of 3 units (15 mM)
of TopA, these figures were of 16.8% and 83.2%
for negative and positive supercoiled
topoisomers, respectively (Fig. 2D).
Inhibition of TopA activity by aporphine
and phenanthrene alkaloids. A total of 18
compounds (6 aporphine and 12 phenanthrene
alkaloids, supplemental Fig. S1)
semisynthesized from the natural alkaloid
boldine (31, and unpublished results) were
selected to test inhibition of growth and
inhibition of S. pneumoniae TopA activity. As
shown in Table 1, previously characterized
clinical isolates (4), either susceptible or
resistant to various antibiotics (including
fluoroquinolone resistant) were tested. The
alkaloids showed equivalent activities against all
isolates, independently of their antibiotic
resistance, suggesting the absence of cross-
resistance. Two phenanthrene alkaloids, with
numbered compounds 16 and 17 (Fig. 3),
showed the greatest inhibition of growth. The
structural elucidation of these compounds was
carried out as described in material and methods.
The in vitro inhibition of TopA
relaxation activity was tested with the 18
compounds using 1 unit of enzyme, i.e. the
amount of enzyme yielding 50% of activity.
Under these conditions, TopA relaxation activity
was inhibited in a concentration-dependent
manner, with IC50 values (average  SD) of
559±72.0 (n=3) for secoboldine (compound 2),
58.2± 3.0 (n=3) for neolitsine (compound 14),
170.4 (n=5) for N-methyl-seconeolitsine
(compound 16) and 170.4 M (n=4) for
seconeolitsine (compound 17) (Figs 4A and 4B).
A good correlation (r2= 0.96) between the
inhibition of TopA activity and the inhibition of
cell growth was observed for these compounds.
These results imply that topoisomerase I is
indeed the in vivo target of the compounds
assayed. The inhibition by the alkaloids was
enhanced by preincubation of the enzyme with
the drug. Lower inhibition was observed when
preincubation was avoided (Fig 4C). These
results suggest that the alkaloid would interact
with the enzyme at the DNA binding site (see
below).
Some inhibition of the relaxation
activity over pBR322 was observed for
compounds 2 and 5 at concentrations 100 M
(Fig. 4A). However, no inhibition for boldine
(Fig. 4A) and the rest of the compounds (data
not shown) was observed at concentrations 
500 M. The inhibition of TopA was tested with
EtBr, a typical DNA intercalant compound. A
pattern compatible with the intercalation of EtBr
into the CCC pBR322 form was observed (Fig.
4C). In addition, preincubation did not change
the observed pattern. These results suggest that
TopA was not inhibited by EtBr.
Human topoisomerase I (TOP1), a
prototype IB topoisomerase, was tested in
relaxation assays with compounds 16 (N-
metilseconeolitsine) and 17 (seconeolitsine)
(Fig. 5A). Activation was observed at low
concentrations and partial inhibition at 50 M, a
concentration at which the pneumococcal TopA
showed full inhibition (data not shown). These
effects on TOP1 could be attributed to the
intercalation of compounds 16 and 17 in the
DNA. As showed in Fig. 5B, both compounds
displace EtBr from calf thymus DNA. At 50%
displacement, the ratio alkaloid/ EtBr was 2.5
(compound 16) and 2.8 (compound 17).
Targeting of TopA in vivo by
seconeolitsine. To asses that TopA is the in vivo
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target of the alkaloids, different attempts were
made to obtain resistant mutants to these
compounds. About 1.2  1010 cells were plated
on agar plates containing 1 to 8  MIC of
seconeolitsine and no resistant bacteria were
obtained. Therefore, to establish that the primary
cellular target for the phenanthrene alkaloids
was indeed topoisomerase I, the topA gene was
cloned under the control of the Pmal promoter
into plasmid pLS1R, yielding plasmid pLS1R-
topA. The activity of this promoter was induced
by maltose (18). The effect of the drug was
tested in the wild type strain R6 (seconeolitsine
MIC = 16 g/ml) carrying either pLS1R or
pLS1R-topA plasmids, at drug concentrations
ranging from 0.25 to 1 MIC. These results
shown that cell growth (Fig. 6A) and division
(Fig. 6B) were affected in a drug concentration-
dependent manner. The growth of R6 carrying
either of these plasmids showed similar kinetics
in the absence or presence of seconeolitsine at 1
 MIC the drug (Fig. 6). In contrast, differences
both in growth inhibition and viability were
observed at 0.25  MIC and 0.5  MIC, where
inhibition by seconeolitsine was attenuated by
the induction of TopA in plasmid pLS1R-topA
(Fig. 6).
Further evidence of the in vivo
inhibition of TopA by seconeolitsine was
obtained from the analysis of topoisomers
distribution of the internal plasmid pLS1 by two-
dimensional agarose gel electrophoresis, a
suitable approach for studying supercoiling
levels (6). This technique allows to separate
DNA molecules by mass and shape. First, pLS1
linking number (Lk) was quantified using two-
dimensional agarose gel electrophoresis with 15
g/ml chloroquine in the second dimension.
Under these conditions, the induced ΔLk of 
monomers was −31. Treatment with compound 
16 at 0.5  MIC and 1  MIC resulted in a time-
dependent increase of plasmid supercoiling (Fig.
7). At 0.5  MIC, supercoiling densities (σ) were 
−0.059, −0.086, and −0.093 at 0, 5 and 30 min 
after drug addition, respectively, indicating that
plasmids became hypernegatively- supercoiled.
Similar results were obtained after treatment at 1
 MIC, where supercoiling densities were
−0.093 and −0.100 at 5 and 30 min respectively. 
Although direct extrapolation from observations
made in small plasmids is not completely
equivalent to the bacterial chromosome, our
results indicate that supercoiling significantly
increases in the presence of seconeolitsine, and
support that TopA is its in vivo target.
Modelling of S. pneumoniae TopA and
docking with alkaloids. We have observed a
46.9% sequence similarity between
topoisomerase I enzymes from E. coli and S.
pneumoniae (Fig. 1A). Therefore, a structural
model of the neumococal TopA was performed
based on the structure of the E. coli enzyme. The
model shows that residues forming the active
site are mainly conserved between E. coli and S.
pneumoniae. The catalytic Tyr319 of E. coli
corresponds to Tyr314 of S. pneumoniae (Fig.
8A). The nucleotide-binding site (binding of the
3’-OH end of the cleaved DNA strand) has been
identified in E. coli at the interface of domains I,
III and IV (14). The equivalent site in S.
pneumoniae TopA presents a strong salt bridge
interaction network at both sides of the cavity.
This network is formed by residues R485-D543-
R102-E546 on one side and E103-R316-D101
on the other side (Fig. 7C). All these residues are
also found in E. coli and S. aureus except for
D546 that is an Ala residue in E. coli and S.
aureus.
Furthermore, drug recognition by the
neumococal TopA enzyme was modelled by
docking using GOLD program with boldine,
secoboldine, seconeolitsine, and N-methyl
seconeolitsine (Fig. 3 and S2). All these ligands
are placed in a similar orientation, stacked
between P486 and R102 in the nucleotide
binding site (supplemental Fig. S2), as observed
for the E. coli topoisomerase I in complex with
nucleotide (13). Among all the tested ligands, N-
methyl-seconeolitsine displays more interactions
with the protein than the remaining alkaloids
(Fig. 8C, supplemental Fig. S2). The larger
number of interactions for phenanthrene
alkaloids (secoboldine, seconeolitsine, N-methyl
seconeolitsine) compared with those with
aporphine skeleton (boldine), can be explained
by the presence of a third benzylic ring. This
extra ring may further stabilize the structures
through both cation- interaction with R102 and
a stacking interaction with P486. Interestingly,
R102, which is critical for the cation-
interaction with the ligand, is also stabilized by a
double salt-bridge interaction with D543 and
E546 (the last one unique to S. pneumoniae).
Moreover, oxygen atoms from methylenedioxy
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groups are establishing polar contacts with
D103, R156 and D543. Furthermore, additional
polar interaction can be predicted between the
secondary amine group of N-methyl-
seconeolitsine and E546. Taking into account all
these data, the large salt bridge network in S.
pneumoniae TopA results in a rigid and narrow
cavity in which N-methyl-seconeolitsine is
strongly stabilized through both the interactions
with different protein residues and by a perfect
fitting in the cavity (Fig. 8B).
Effect of seconeolitsine and N-methly-
seconeolitsine in human cell viability. At the two
concentrations assayed (30 and 100 M), neither
N-methyl-seconeolitsine nor seconeolitsine
affected neutrophil apoptosis (Fig. 9). In
contrast, seconeolitsine, at the highest
concentration tested (100 M), caused a small
but significant decrease in neutrophil survival
(Fig. 9). Nevertheless this concentration was
nearly 5 fold higher than that necessary to exert
antibiotic activity.
DISCUSSION
Two main approaches can be used for
the discovery of new antibiotics. The first
approach is based on the screening of natural
products for bacteria growth inhibition followed
by the subsequent identification of the cellular
target. The second uses the knowledge of the
structure of essential enzyme targets to design
different compounds. In this study both
approaches have been successfully used to
identify new alkaloid antibiotics. We have
characterized for the first time the topoisomerase
I enzyme of S. pneumoniae and completed the
characterization of the DNA topoisomerase
complement of this pathogen. Topoisomerase I
is the unique DNA topoisomerase of type I in
this bacterium and has enzymatic features
similar to those found in Gram-negative
bacteria, being able to relax negatively-
supercoiled DNA, but not positively-supercoiled
(Fig. 2).
A previous study carried out by Tse-
Dinh’s group evaluated the capability of
different compounds to inhibit topoisomerase I
enzymes of Gram-negative bacteria (E. coli and
Yersinia pestis) (15). Among them,
stephenanthrine (20-100 µM), was found to
inhibit the relaxation activity of E. coli
topoisomerase I via stabilization of the cleavage
complex. However, this alkaloid did not affect
bacterial growth at these concentrations, being
the MIC of 60 and 100 µM for Bacillus subtilis
(Gram-positive organism) and E. coli,
respectively. These findings led us to test the
activity of various boldine-derived compounds
presenting a chemical structure similar to
stephenanthrine. Among them, N-methyl-
seconeolitsine and seconeolitsine displayed the
most potent inhibitory activity of bacterial
growth at concentrations within the range
required for inhibition of the relaxation activity
of S. pneumoniae topoisomerase I (Fig. 4, Table
1). Moreover, these compounds also inhibited
the growth of S. pneumoniae clinical isolates
resistant to other chemically unrelated
antibiotics used to treat pneumococcal infections
(Table 1); including fluoroquinolones that target
type II topoisomerases.
Attempts to obtain mutants resistant to
the alkaloids were unsuccessful. These results
suggest that the alteration of the single
topoisomerase of type IA in S. pneumoniae
could be lethal, especially if the alteration would
be at the DNA-binding site. In agreement, E.coli
cells lacking their two type IA topoisomerases
(TopA and TopB) are found to be nonviable
(32).
Evidence for in vivo targeting of TopA
by seconeolitsine was provided by the protection
against growth inhibition when TopA was
overproduced (Fig. 6). In fact, the increase in
supercoiling of an internal plasmid in the
presence of the alkaloid suggest an inhibition of
TopA. This increase in supercoiling could be
also caused by activation of gyrase or by
inhibition of topoisomerase IV. However, these
effects were not observed in the in vitro
activities of purified pneumococcal gyrase and
topoisomerase IV in the presence of N-methyl-
seconeolitsine (data not shown). These results
suggest that TopA is the intracellular target of
compounds N-methyl-seconeolitsine and
seconeolitsine and that these alkaloids might be
useful in the treatment of infectious diseases
caused by multidrug-resistant isolates. Although
pharmacokinetic studies are required, our
toxicological studies suggest that N-methyl-
seconeolitsine and seconeolitsine (30 M) did
not affected human neutrophil viability (Fig. 8).
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It has been proposed that the reaction
cycle of topoisomerase I involves the opening
and closing of the enzyme. In order for DNA to
bind near the active site, the enzyme must adopt
an open (or partially open) conformation (13).
After the cleavage reaction takes place, the
protein adopts an open conformation in which
the protein forms a bridge between the two ends
of the broken DNA strand. The opening of the
enzyme would allow the entrance of another
strand into the central hole. For the religation
step to take place, the enzyme must bring the
two ends of the broken strand together by
bringing domains I and III together while
keeping the passing strand inside the central hole
of the enzyme. Clearly, different openings of the
enzyme are required to display full activity. In
this way, docking calculations with alkaloids
indicate that they can be accommodated at the
nucleotide-binding site of the closed
conformation of topoisomerase I. In this site
alkaloids are in close contact with domains I, III
and IV (Fig. 7, supplemental Fig. S2) and
establish strong interactions (cation-,
hydrophobic and polar interactions) with
residues of the nucleotide-binding site. Boldine
presents a more flexible structure without the
extended  cloud of the seconeolitsine or N-
methyl-seconeolitsine, therefore preventing a
strong stabilization through cation- interaction,
as predicted for seconeolitsine or N-methyl-
seconeolitsine. These strong interactions
together with the fine fitting observed between
the nucleotide-binding site and the alkaloid,
should block the opening mechanism required
for topoisomerase I to be fully active. Therefore,
avoidance of DNA binding may explain the
strong inhibitory effect observed for these
ligands. In agreement with that hypothesis, the
inhibitory effect exerted by these alkaloids was
enhanced prior to DNA binding. Thus, alkaloid-
topoisomerase interactions seem to occur at the
initial steps (i.e. in the closed conformation) and
very likely in simultaneous interaction with the
different domains involved in the opening
mechanism of the enzyme.
Low concentrations of seconeolitsine
and N-methyl-seconeolitsine seemed to activate
the in vitro relaxation activity of human
topoisomerase I (TOPO1), a prototype IB
topoisomerase. However, the in vitro
intercalation of these compounds in the DNA
(Fig. 5B) would suggest that the alterations of
TOPO1 activity could be attributed to this
intercalation. In agreement, a similar effect was
observed when the relaxing activity of TopA
was tested in the presence of EtBr (Fig. 5B).
Higher alkaloid concentrations seemed
to inhibit the in vitro activity of human TOPO1
without inducing apoptosis in human cells. In
contrast, camptothecin, a selective inhibitor of
TOPO1 used as antitumor drug, induce
apoptosis. It binds simultaneously both to the
DNA and to TOP1 and estabilize the cleavage
complex formed by TOP1-DNA and the drug.
Then, the collision of these cleavage complexes
with replication forks induce double-strand
breaks that led to apoptosis (33). Therefore, it is
likely that either alkaloid interaction with
TOPO1 occurs before the single-stranded DNA
cleavage is produced, since apoptosis was not
detected, or that did not interact with the
enzyme.
In conclusion, in the present study we
have isolated and purified a new antibiotic target
from S. pneumoniae, topoisomerase I. Through
the semi-synthesis of two new antibiotics,
seconeolitsine and N-methly-seconeolitsine, we
have proved that topoisomerase I inhibition
results in the blockade of bacteria growth
without affecting the viability of human cells.
These compounds did not cause any cytotoxic
effect on human neutrophils at the
concentrations required to exert antibiotic
activity. Thus, seconeolitsine and N-methyl-
seconeolitsine can be envisaged as two new
therapeutic candidates for the treatment of S.
pneumoniae infections resistant to other
antibiotics and open a new scenario for
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FIGURE LEGENDS
FIGURE 1. Identification and purification of S. pneumoniae DNA topoisomerase I. A, alignment of
E. coli and S. pneumoniae TopA proteins. Colour codes correspond to the four structural domains showed
in Fig. 7. The catalytic Tyr residue (Tyr319 for E. coli and Tyr314 for S. pneumoniae) is coloured in
magenta, shadowed in yellow and labelled with a magenta asterisk. Residues in boldface labelled with a
black asterisk and shadowed in yellow form part of the nucleotide binding site and are involved in the
salt-bridge interaction network. B, expression of TopA and steps of purification. Cultures of M15
(pREP4) containing pQE-SPNtopA were grown in LB medium and induced with IPTG as described in
Materials and Methods. Samples of 10 l were electrophoresed in a SDS-10% polyacrylamide gel.
Polypeptides were revealed by Coomassie blue staining. Lanes: CE (12 g) after 0 and 30 min induction;
Ni-NTA column, fraction that did not bind to the column and eluted in the loading (9 g ), fraction eluted
with 10 mM (2 g), with 60 mM (0.5 g) and 100 mM (1 g) imidazol. Sizes of protein markers (Mw)
are indicated to the left.
FIGURE 2. TopA has nicking and closing activities. Plasmid pBR322 (1.77 nM) was incubated with
purified topoisomerase I at the indicated concentrations for 1h at 37ºC. Samples were processed and
analysed as described under "Material and Methods". OC, relaxed open circles; CCC, covalently closed
circles; RC, relaxed circular plasmids forms. Mw, molecular weight standard. A, gel run in the absence of
EtBr. B, the same samples run in A were run in the presence of 0.5 µg/ml of EtBr. C, TopA activity on
positively-supercoilied pBR322. In wells labeled as (+) for EtBr, the pBR322 was incubated in the
presence of 2 µg/ml of EtBr for 15 min at 4ºC before the incubation with TopA. In the well labeled as
(+,-), pBR322 previously treated with 2 µg/ml of EtBr was treated with isoamylalcohol to remove EtBr
and further incubated with TopA. D, topoisomer distribution of pBR322 after TopA treatment. Plasmid
DNA was subjected to two-dimensional agarose electrophoresis. E, illustration of pBR322 topoisomer
distribution after treatment with 15 mM TopA in two-dimensional electrophoresis in agarose gels run in
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the presence of 1 and 2 g/ml chloroquine in the first and second dimensions, respectively. Negative
supercoiled topoisomers are in white and positive supercoiled in black. A black arrowhead indicates the
topoisomer that migrated with Lk = 0 in the second dimension.
FIGURE 3. Chemical structures of the most relevant aporfine and phenantrene alkaloids used in
this study.
FIGURE 4. TopA is inhibited by phenanthrene alkaloids. A, inhibition of TopA by boldine, compound
2 (secoboldine) and compound 5 (N-methyl-secoboldine). Supercoiled pBR322 (0.5 µg) was treated with
1 unit of purified TopA in 15 µl reactions containing the alkaloids at the concentrations (M) indicated.
Mw, molecular weight standard, S, covalently-closed supercoiled pBR322 used as substrate. B, inhibition
of TopA by compounds 16 (N-metilseconeolitsine), 17 (seconeolitsine) and 14 (neolitsine). Reactions
were carried out as in A. C, the inhibition of TopA by seconeolitsine is enhanced by preincubation of the
enzyme with the alkaloid. pBR322 was treated with 1 unit of purified TopA in the absence of the
inhibitor (0), or in the presence of 30 M of compound 17 with (+) or without () preincubation during
10 min at 4ºC. D, effect of EtBr on TopA activity. Reactions were carried out as in A containing the
compound at the indicated concentrations (M).
FIGURE 5. Human TOPO1 is not inhibited by phenantrene alkaloids. A, effect of compounds 16 (N-
metylseconeolitsine) and 17 (seconeolitsine) on the enzymatic activity. Supercoiled pBR322 was treated
with 1 unit of enzyme in the absence (0) or in the presence of various concentrations of the alkaloids with
or without () preincubation 30 M of compound 17. B, EtBr displacement assay of compounds 16 and
17. Fluorescence is expressed as the percentage of the maximum fluorencence signal when EtBr was
bound to the DNA in the absence of the alkaloids and was corrected for background fluorencence of EtBr
in solution.
FIGURE 6. The overexpression of TopA allows cell survival in the presence of seconeolitsine.
Exponentially-growing cultures of R6 carrying pLS1R (open symbols) or pLS1R-topA (full symbols)
were grown in AGCH containing 0.8% sucrose to DO620 = 0.6. At this moment, cultures were diluted 20-
fold in medium containing 0.4% sucrose and 0.4% maltose. A, growth and B, viability in the absence or
the presence of compound 17 (seconeolitsine) at different concentrations were determined. Initial OD620
values were 0.17 for pLS1R and 0.15 for pLS1R-topA. Initial viable values were 6.6  107 cfu/ml for
pLS1R and 3.2  107 cfu/ml for pLS1R-topA.
FIGURE 7. Treatment with seconeolitsine causes hypernegative supercoiling in plasmid DNA. An
exponentially growing culture of R6 in AGCH carrying plasmid pLS1 was treated at OD620=0.4 with
seconeolitsine (compound 17) at 0.5  MIC and 1  MIC. Purified plasmid DNA from samples collected
at 5 and 30 min after treatment was subjected to two-dimensional agarose gel electrophoresis in the
presence of 5 µg/ml chloroquine in the first dimension and 15 µg/ml in the second dimension. It was
previously determined that 15 µg/ml of chloroquine introduces 31 positive supercoils. A black arrowhead
indicates the topoisomer that migrated with Lk = 0 in the second dimension. An empty arrowhead
indicates the most abundant topoisomer. The corresponding supercoiling density () is indicated below
each autoradiogram.
FIGURE 8. Structural modelling of the interaction of S. pneumoniae topoisomerase I with alkaloid
antibiotics. A, overall structure of the 67 kDa fragment of S. pneumoniae TopA showing the four
structural domains and the catalytic Tyr314 residue (magenta sticks). B, N-methyl-seconeolitsine
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(represented as blue spheres) bound to the nucleotide-binding site of topoisomerase I. C, stereo view
representation describing details of ligand recognition by topoisomerase I as obtained by docking
calculations. The view shows the interactions between the nucleotide-binding site and N-methyl-
seconeolitsine. The residues forming the binding site are drawn as capped sticks. Carbon atoms of the
ligand are in yellow. Hydrogen bonds and salt-bridge interactions are represented as dashed lines.
FIGURE 9. Effect of compounds 16 and 17 on cell viability. A, B, effects of compounds 16 and 17 on
early apoptosic (annexin V+, PI–), late apoptotic and/or necrotic (annexin V+ and PI+), and viable
nonapoptotic (annexin V– and PI–) cells at 24 h of culture of human neutrophils. Columns are mean 
SEM. of 7-9 independent replicates; *P<0.05 compared to vehicle. A representative flow cytometry panels
showing the effect of compounds 16 and 17 on human neutrophil apoptosis have been included.
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TABLE 1.
Susceptibilities of S. pneumoniae strains to boldine derivatives
Strains Resistance Patterna MIC (M) a of
2 3 4 5 6 7 11 12 13 14 16 17 23
R6 S 500 500 >250 500 250 250 125 125 500 125 16 16 62
ATCC 6303 S 1000 1000 >250 500 >250 250 125 125 500 125 16 16 125
CipS8 S 500 500 >250 500 >250 125 125 125 500 125 16 16 62
CipS9 S 1000 1000 >250 1000 >250 250 125 125 500 125 16 16 125
CipR20 PTCEClSxTCip 1000 500 >250 250 >250 250 125 125 500 62 8 16 125
CipR16 PSxTCip 1000 1000 >250 500 >250 500 125 125 500 125 16 16 62
CipR8 PSxTCip 500 500 >250 500 >250 250 62 125 500 62 8 8 125
CipR42 PTEClCip 1000 1000 >250 500 >250 250 125 125 500 62 8 8 125
CipR45 TEClCip 500 500 >250 1000 >250 250 125 125 500 62 8 16 125
CipR68 Cip 500 500 >250 500 >250 250 125 125 500 62 8 8 125
CipR5 EClCip 500 500 >250 500 >250 250 125 125 500 62 16 16 62
CipR15 SxTCip 1000 1000 >250 500 >250 250 125 125 500 62 16 8 62
a S, susceptible to all antibiotics tested; P, resistant to penicillin (MICs of 0.12 to 4 g/ml); T, resistant to tetracycline (MICs 4 g/ml); C, resistant to
chloramphenicol (MICs 8g/ml); E, resistant to erythromycin (MICs 0.5 g/ml); Cl, resistant to clindamycine (MICs 1 g/ml) Cp, resistant to
ciprofloxacin (MICs 4 g/ml), SxT, resistant to cotrimoxazole (MIC 4 g/ml for trimethoprim and 76 g/ml for sulfamethoxazole).
bMICs for compounds B (boldine), 10, 19, 20, 21 and 22 were 1000 M in all cases. The chemical structures of the compounds used are showed in
supplemental Fig. S1.
